在一項臨床試驗中，患有分杈病變的患者使用Cordis心臟病學公司(Miami, FL, USA)的Cypher sirolimus釋放冠狀動脈支架治療，在晚期面積喪失、再次接受治療和再次堵塞方面，療效顯著優于Boston科學公司(Natick, MA, USA)的paclitaxel釋放Taxus支架。

這項包括205例患者的隨機對照臨床試驗中發現，在6個月的時候，患有分杈病變的患者使用Cypher支架臂比Taxus支架臂出現再狹窄的可能性要低3倍。接受Cypher支架的患者在大血管和臨近側支血管晚期面積喪失等方面，效果較令人滿意。

這項研究結果在2005年11月Dallas(TX, USA)舉行的美國心臟學會年度科學會議上進行了報道。這些發現得到了超過40項臨床試驗項目的支持。
 
Sirolimus-Eluting Stent Bests Taxus Stent
 
Patients with bifurcation lesions fared significantly better in a clinical trial when treated with the Cypher sirolimus-eluting coronary stent of Cordis Cardiology (Miami, FL, USA) than with the paclitaxel-eluting Taxus stent of Boston Scientific (Natick, MA, USA) in areas of late loss, re-treatment, and re-blockage.

The 205-patient randomized, comparative trial found that at six months, patients with bifurcations in the Cypher stent arm were three times less likely to experience restenosis than patients in the Taxus stent arm of the study. The late loss results in the main vessel and adjoining side branch also favored those patients treated with the Cypher stent.

The study results were presented at the annual Scientific Sessions of the American Heart Association in November 2005 in Dallas (TX, USA). The findings are supported by a clinical trial program that included more than 40 studies.